balance equationreview2025-06-30
Difference 304754000 exceeds tolerance 4566019.000. Presentation or filing-vintage differences need review.
Revenue
$1.29B
Fiscal year ended 2026-06-30Operating income
$231.44M
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported revenue of $1.29B and net income of $164.49M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ALNYLAM PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.10B | $1.25B | $773.69M | $594.19M | $593.17M | $500.92M | $659.82M | $494.33M | $439.72M |
| Cost of revenue | $298.26M | $267.72M | $197.23M | $142.03M | $70.18M | $102.65M | $81.98M | $67.27M | $54.61M | $71.98M |
| Gross profit | $992.69M | $829.31M | $1.05B | $631.66M | $524.01M | $490.52M | $418.94M | $592.55M | $439.72M | $367.74M |
| Operating income | $231.44M | $131.72M | $367.98M | -$16.20M | $18.08M | -$105.16M | -$76.90M | $48.61M | -$43.44M | -$116.40M |
| Net income | $164.49M | $111.54M | $251.08M | -$72.23M | -$18.25M | -$83.76M | -$111.57M | -$16.89M | -$65.94M | -$137.87M |
| Research & development | $413.13M | $372.22M | $358.81M | $323.62M | $265.12M | $300.17M | $270.93M | $294.14M | $261.00M | $272.14M |
| Weighted-average diluted shares | shares 138.28M | Unavailable | shares 137.35M | shares 130.63M | shares 129.68M | Unavailable | shares 128.59M | shares 126.73M | shares 126.14M | Unavailable |
| Pretax income | $177.81M | $86.26M | $238.97M | -$41.31M | -$2.37M | -$193.96M | -$108.66M | -$11.17M | -$63.59M | -$137.69M |
| Income tax expense | $13.31M | -$25.28M | -$12.12M | $30.92M | $15.88M | -$110.20M | $2.91M | $5.72M | $2.35M | $183.00K |
| Diluted EPS | $1.21 | Unavailable | $1.84 | $-0.55 | $-0.14 | Unavailable | $-0.87 | $-0.13 | $-0.52 | Unavailable |
| Selling, general & administrative | $347.92M | $325.37M | $322.08M | $323.31M | $239.95M | $295.34M | $220.99M | $248.40M | $210.80M | $198.12M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966.43M | $1.10B | $968.49M | $681.88M | $812.69M |
| Total assets | $5.56B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | $3.83B |
| Current assets | $4.62B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | $2.98B |
| Total liabilities | $4.20B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | $4.05B |
| Current liabilities | $1.51B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $941.71M | $967.79M |
| Total equity incl. NCI | $1.35B | $789.18M | $233.89M | $555.34M | $426.14M | $67.09M | $32.35M | -$3.07M | -$219.27M | -$220.64M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $97.11M | $82.72M | $75.38M | $71.69M | $65.58M | $78.51M | $75.99M | $83.98M | $93.99M | $89.15M |
| Accounts receivable | $912.74M | $777.57M | $964.77M | $567.11M | $418.04M | $405.31M | $353.85M | $309.48M | $321.38M | $327.79M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $108.02M | $115.72M | $117.59M | $102.39M | $97.40M | $88.42M | $70.80M | $73.98M | $78.15M | $55.52M |
Cash flow
| Metric | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | Unavailable | $163.56M | $351.03M | $127.81M | -$118.31M | -$94.66M | $43.71M | $124.16M | -$81.52M | -$29.80M |
| Capital expenditures | Unavailable | $23.29M | $12.14M | $14.29M | $8.97M | $9.09M | $4.19M | $8.02M | $12.97M | $15.31M |
| Investing cash flow | Unavailable | -$37.17M | $501.11M | -$141.38M | $113.77M | -$52.91M | -$30.25M | $33.94M | -$67.62M | -$240.66M |
| Financing cash flow | Unavailable | $45.32M | -$474.27M | $79.68M | $44.08M | $31.00M | $102.76M | $131.50M | $28.91M | $39.23M |
| Net change in cash | Unavailable | $166.00M | $376.94M | $93.61M | $53.60M | -$133.85M | $131.30M | $286.47M | -$130.16M | -$220.33M |
| Stock-based compensation | Unavailable | $71.63M | $108.21M | $111.68M | $56.71M | $91.64M | $45.80M | $89.29M | $45.35M | $41.99M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | $13.51M | $13.80M | $13.94M | $14.40M | $14.17M | $13.98M | $15.00M | $13.52M | $13.48M |
Derived
| Metric | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | $140.26M | $338.89M | $113.52M | -$127.28M | -$103.76M | $39.52M | $116.14M | -$94.49M | -$45.10M |
| Gross margin | 76.9% | 75.6% | 84.2% | 81.6% | 88.2% | 82.7% | 83.6% | 89.8% | 89.0% | 83.6% |
| Operating margin | 17.9% | 12.0% | 29.5% | -2.1% | 3.0% | -17.7% | -15.4% | 7.4% | -8.8% | -26.5% |
| FCF margin | Unavailable | 12.8% | 27.1% | 14.7% | -21.4% | -17.5% | 7.9% | 17.6% | -19.1% | -10.3% |
| SBC / revenue | Unavailable | 6.5% | 8.7% | 14.4% | 9.5% | 15.5% | 9.1% | 13.5% | 9.2% | 9.6% |
| Current ratio | 3.05x | 2.76x | 2.54x | 2.80x | 3.04x | 2.78x | 2.75x | 3.01x | 3.17x | 3.08x |
| Revenue YoY growth | 66.9% | 84.9% | 149.3% | 17.3% | 20.2% | 34.9% | -33.3% | 107.0% | 54.8% | 31.2% |
| Net margin | 12.7% | 10.2% | 20.1% | -9.3% | Unavailable | -14.1% | -22.3% | Unavailable | Unavailable | -31.4% |
| R&D / revenue | 32.0% | 33.9% | 28.7% | 41.8% | 44.6% | 50.6% | 54.1% | 44.6% | 52.8% | 61.9% |
| CapEx / revenue | Unavailable | 2.1% | 1.0% | 1.8% | 1.5% | 1.5% | 0.8% | 1.2% | 2.6% | 3.5% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 7.5% | -29.3% | -5.1% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALNY in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing
10-K · Filed 2025-02-13View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2025-03-31
Difference 310705000 exceeds tolerance 4213811.000. Presentation or filing-vintage differences need review.